Greco Salvatore, Salatiello Alessandro, Fabbri Nicolò, Riguzzi Fabrizio, Locorotondo Emanuele, Spaggiari Riccardo, De Giorgi Alfredo, Passaro Angelina
Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.
Department of Internal Medicine, Ospedale del Delta, Via Valle Oppio 2, 44023 Ferrara, Italy.
Biomedicines. 2023 Mar 9;11(3):831. doi: 10.3390/biomedicines11030831.
Risk prediction models are fundamental to effectively triage incoming COVID-19 patients. However, current triaging methods often have poor predictive performance, are based on variables that are expensive to measure, and often lead to hard-to-interpret decisions. We introduce two new classification methods that can predict COVID-19 mortality risk from the automatic analysis of routine clinical variables with high accuracy and interpretability. SVM22-GASS and Clinical-GASS classifiers leverage machine learning methods and clinical expertise, respectively. Both were developed using a derivation cohort of 499 patients from the first wave of the pandemic and were validated with an independent validation cohort of 250 patients from the second pandemic phase. The Clinical-GASS classifier is a threshold-based classifier that leverages the General Assessment of SARS-CoV-2 Severity (GASS) score, a COVID-19-specific clinical score that recently showed its effectiveness in predicting the COVID-19 mortality risk. The SVM22-GASS model is a binary classifier that non-linearly processes clinical data using a Support Vector Machine (SVM). In this study, we show that SMV22-GASS was able to predict the mortality risk of the validation cohort with an AUC of 0.87 and an accuracy of 0.88, better than most scores previously developed. Similarly, the Clinical-GASS classifier predicted the mortality risk of the validation cohort with an AUC of 0.77 and an accuracy of 0.78, on par with other established and emerging machine-learning-based methods. Our results demonstrate the feasibility of accurate COVID-19 mortality risk prediction using only routine clinical variables, readily collected in the early stages of hospital admission.
风险预测模型是有效分诊新冠病毒肺炎(COVID-19)患者的基础。然而,当前的分诊方法往往预测性能不佳,基于测量成本高昂的变量,且常常导致难以解释的决策。我们引入了两种新的分类方法,它们能够通过对常规临床变量的自动分析,高精度且具有可解释性地预测COVID-19的死亡风险。SVM22-GASS分类器和临床GASS分类器分别利用了机器学习方法和临床专业知识。两者均使用了来自疫情第一波的499名患者的推导队列进行开发,并在来自疫情第二阶段的250名患者的独立验证队列中进行了验证。临床GASS分类器是一种基于阈值的分类器,它利用了新冠病毒2型严重程度综合评估(GASS)评分,这是一种特定于COVID-19的临床评分,最近显示出其在预测COVID-19死亡风险方面的有效性。SVM22-GASS模型是一种二元分类器,它使用支持向量机(SVM)对临床数据进行非线性处理。在本研究中,我们表明SMV22-GASS能够以0.87的曲线下面积(AUC)和0.88的准确率预测验证队列的死亡风险,优于此前开发的大多数评分。同样,临床GASS分类器以0.77的AUC和0.78的准确率预测了验证队列的死亡风险,与其他已确立的和新兴的基于机器学习的方法相当。我们的结果证明了仅使用在入院早期易于收集的常规临床变量准确预测COVID-19死亡风险的可行性。